Nkarta (NASDAQ:NKTX) Azioni

NKARTA INC

Nkarta

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Nkarta Inc

<a href="https://www.bloomberg.com/news/articles/2025-07-21/oracle-in-talks-for-100-million-skydance-paramount-cloud-deal">https://www.bloomberg.com/news/articles/2025-07-21/oracle-in-talks-for-100-million-skydance-paramount-cloud-deal</a>

News

General

ORCL

PARA

'Oracle in Talks for $100 Million Skydance-Paramount Cloud Deal'- Bloomberg

On Monday, AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 trial of Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy.
The <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2025/tagrisso-plus-chemotherapy-demonstrated-statistically-significant-and-clinically-meaningful-improvement-in-overall-survival-in-egfr-mutated-advanced-lung-cancer.html" rel="noreferrer noopener">study</a> demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of OS compared to Tagrisso monotherapy for patients with 1st-line locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">non-small cell lung cancer (NSCLC)</a>.​
The final OS analysis demonstrates consistent survival benefit, as reported in the interim OS results.
It builds on the previously presented primary endpoint data, demonstrating the longest-reported median progression-free survival (PFS) in this setting.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46444819/astrazenecas-therapy-for-rare-protein-deposit-condition-fails" rel="noreferrer noopener">AstraZeneca&#8217;s Experimental Therapy Stumbles In Late-Stage Study For Rare Protein Deposit Condition</a>
In September 2023, AstraZeneca released data from the FLAURA2 Phase 3 trial showing Tagrisso (osimertinib) in combination with chemotherapy reduced the risk of disease progression or death by 38% compared to Tagrisso alone in patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).
According to the investigator&#8217;s assessment, the combination extended median progression-free survival by 8.8 months <a target="_blank" href="https://www.benzinga.com/general/biotech/23/09/34438541/astrazenecas-reinforces-hold-in-lung-cancer-settings-touts-promising-data-from-three-trials?_gl=1&#x2A;8ut96x&#x2A;_gcl_au&#x2A;MTA0Mzg4NjY1MC4xNzUwMDYyNTg3&#x2A;_ga&#x2A;R1MyLjEuczE3NTMwODY0MjgkbzE4OSRnMSR0MTc1MzA5OTgzMSRqNjAkbDAkaDA.&#x2A;_ga_V7ZK73W7N0&#x2A;czE3NTMwODY0MjgkbzE4OSRnMSR0MTc1MzA5OTgzMSRqNjAkbDAkaDA." rel="noreferrer noopener">compared to Tagrisso alone</a>.&nbsp;
In March 2024, results from the FLAURA2 Phase 3 <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-the-addition-chemotherapy-showed-favourable-trend-overall-survival-egfr-mutated-advanced-lung-cancer-further-follow-flaura2-phase-iii-trial.html#!" rel="noreferrer noopener">trial</a> showed Tagrisso, with the addition of chemotherapy,​ provided a clinically meaningful and consistent benefit in subsequent outcomes after disease progression in patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.
Tagrisso, with the addition of chemotherapy, also demonstrated a favorable trend toward overall survival improvement at two years of follow-up.
With longer follow-up, the safety profile of Tagrisso plus chemotherapy continues to be manageable and consistent with the established profiles of the individual medicines.
Adverse event (AE) rates were higher in the Tagrisso plus chemotherapy arm, driven by well-characterised chemotherapy-related AEs.&nbsp;Discontinuation rates due to AEs and on-target toxicities were low in both arms of the trial.
Based on the FLAURA2 Phase 3 trial, Tagrisso plus chemotherapy is approved in over 80 countries, including the U.S., EU, China, and Japan.
Price Action: AZN stock closed lower by 0.10% at $68.72 on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46514251/taiwan-semiconductor-plans-four-new-fabs-as-ai-gold-rush-continues" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor Plans Four New Fabs As AI Gold Rush Continues</a></li>
</ul>
Photo by Piotr Swat via Shutterstock

Biotech

Large Cap

Health Care

AstraZeneca's Multi-Billion Dollar Cancer Drug Tagrisso Improves Overall Survival In Patients With Advanced Lung Cancer

TELUS is excited to announce a $2-billion investment to deliver our global-leading broadband services across Ontario and Quebec over the next five years. This investment comes as a result of the CRTC confirmation of the wholesale fibre-to-the-premise (FTTP) framework and serves as a complement to our wholesale fibre access agreements, allowing TELUS to deliver national scale, accelerate network builds and drive investment, competition and affordability in Canada. This marks a significant milestone in TELUS' ongoing efforts to bring Canada's fastest and most reliable broadband services to more communities – fueling economic growth and ensuring all Canadians have access to next generation digital services.
"Today's announcement regarding our TELUS broadband fibre and wireless expansion reinforces our long-standing commitment to sustained, transformative investments that advance economic and social prosperity for all Canadians. Against a backdrop of macroeconomic uncertainty, TELUS stands as one of the few companies committing to bold, future-focused infrastructure investments that bolster digital inclusion and bridge digital divides by bringing globally leading connectivity to communities of all sizes," said Darren Entwistle, President and CEO of TELUS. "Notably, by expanding our world-leading TELUS broadband network in Ontario and Quebec&nbsp;in a synergistic combination with our wholesale fibre access, millions of citizens and businesses will be empowered with the connectivity needed to fully participate in the digital economy, unlocking benefits for generations to come. The $2 billion we are investing in Ontario and Quebec over the next five years transcends traditional connectivity; it is powering&nbsp;new and advanced digital services&nbsp;including, AI-fuelled smart home energy management, next-generation healthcare, affordable security and exciting entertainment solutions – driving innovation across all sectors of the economy and our societies, propelling our productivity and quality of life as a nation."
New fibre-optic infrastructure will also serve as the backbone of TELUS' world-leading 5G wireless network, ensuring that people and businesses have the tools they need to manage their lives and drive business success in our digital world. Importantly, TELUS PureFibre is 85% more energy-efficient than copper, and more durable against extreme weather and environmental factors, making it a more sustainable and reliable technology.
This $2-billion investment will be part of our annual budget and will be supported by&nbsp;investments from our strategic build partnerships. This investment program comes on top of the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4472492-1&amp;h=766511840&amp;u=https%3A%2F%2Fwww.telus.com%2Fen%2Fabout%2Fnews-and-events%2Fmedia-releases%2Ftelus-investing-7-0-billion-in-canada-through-2029-to-enhance-connectivity-support-canadian-ai-leadership-and-fuel-economic-growth&amp;a=%2470+billion+TELUS+announced">$70 billion TELUS announced</a> earlier this year to enhance connectivity, support Canadian AI leadership and fuel economic growth through 2029, and builds on the more than $276 billion TELUS has committed since 2000 to boost productivity and support a robust national economy.
These investments are consistent with TELUS' guidance for 2025, including capital expenditures, as disclosed in the company's fourth quarter 2024 results and 2025 targets news release dated February 12, 2025 and in the company's first quarter 2025 results news release dated May 9, 2025. This investment profile aligns with the company's longer-term capital-intensity aspirations and our deleveraging target for 2027, including the removal of the dividend reinvestment plan discount.
We're always building Canada.

TELUS invests $2BT o Deliver Its Global-Leading Broadband Services Across Ontario And Quebec Over The Next Five Years

Ovintiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OVV#NYSE">OVV</a>) has outperformed the market over the past 5 years by 14.32% on an annualized basis producing an average annual return of 28.72%. Currently, Ovintiv has a market capitalization of $10.13 billion. 
Buying $1000 In OVV: If an investor had bought $1000 of OVV stock 5 years ago, it would be worth $3,527.65 today based on a price of $38.91 for OVV at the time of writing.
<h3>Ovintiv's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753134313_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $1000 Invested In Ovintiv 5 Years Ago Would Be Worth Today

Peapack Gladstone Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGC#NASDAQ">PGC</a>) reported quarterly earnings of $0.45 per share which missed the analyst consensus estimate of $0.62 by 27.07 percent. This is a 7.14 percent increase over earnings of $0.42 per share from the same period last year. The company reported quarterly sales of $69.741 million which missed the analyst consensus estimate of $69.775 million by 0.05 percent. This is a 23.22 percent increase over sales of $56.597 million the same period last year.

Earnings

Earnings Misses

Peapack Gladstone Finl Q2 2025 GAAP EPS $0.45 Misses $0.62 Estimate, Sales $69.741M Miss $69.775M Estimate

AstraZeneca today announces $50 billion of investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&amp;D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in America and worldwide.
The cornerstone of this landmark investment is a new multi-billion dollar US manufacturing facility that will produce drug substances for the Company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of-the-art center will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024.
The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimize production.
The $50 billion investment across our R&amp;D and manufacturing footprint in the US over the next five years also includes:
<ul>
<li>Expansion of our R&amp;D facility in Gaithersburg, Maryland</li>
<li>State-of-the-art R&amp;D center in Kendall Square, Cambridge, Massachusetts</li>
<li>Next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California</li>
<li>Continuous manufacturing expansion in Mount Vernon, Indiana</li>
<li>Specialty manufacturing expansion in Coppell, Texas</li>
<li>New sites to supply clinical trials</li>
<li>Our growing research and development investment in novel medicines</li>
</ul>
Collectively, these investments will help deliver AstraZeneca's ambition of reaching $80 billion in Total Revenue by 2030, of which we expect 50% would be generated in the US.
Howard Lutnick, US Secretary of Commerce, said: "For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here."
Governor Glenn Youngkin, Commonwealth of Virginia, said: "I want to thank AstraZeneca for choosing Virginia as the cornerstone for this transformational investment in the United States. This project will set the standard for the latest technological advancements in pharmaceutical manufacturing, creating hundreds of highly skilled jobs and helping further strengthen the nation's domestic supply chain. Advanced manufacturing is at the heart of Virginia's dynamic economy, so I am thrilled that AstraZeneca, one of the world's leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth."
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030. I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia's desire to create highly skilled jobs in science and technology, and will strengthen the country's domestic supply chain for medicines."

AstraZeneca To Invest $50B In The U.S. By 2030, Building On America's Global Leadership In Medicines Manufacturing And R&D; Investment Will Support AstraZeneca's Ambition To Reach $80B Revenue By 2030, With 50% Generated In The U.S

Agilysys Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>) reported financial results for the first quarter after the market close on Monday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/07/b46531818/agilysys-announces-record-revenue-of-76-7m-in-fiscal-2026-first-quarter">of the report</a>.
<ul class="wp-block-list">
<li>Q1 Revenue: $76.7 million, versus <a href="http://benzinga.com/quote/agys/earnings">estimates</a> of $74.35 million</li>
</ul>
<ul class="wp-block-list">
<li>Q1 Adjusted EPS: 33 cents, versus estimates of 36 cents</li>
</ul>
Total revenue increased 20.7% year-over-year. Recurring revenue totaled $48.6 million and subscription revenue increased 44.3% year-over-year. 
The hospitality software solutions company reported free cash flow of negative $5 million. Agilysys ended the quarter with a cash balance of $55.6 million.
&#8220;We continue to enjoy excellent selling momentum with consistent, robust demand for the modernized state-of-the-art cloud-native ecosystem of hospitality-focused software solutions. Strong sales drove the recurring and services revenue backlog to record levels, despite strong implementation success and record services revenue,&#8221; said Ramesh Srinivasan, president and CEO of Agilysys.
Outlook: Agilysys expects fiscal 2026 revenue to be in the range of $308 million to $312 million versus estimates of $309.99 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company also guided for subscription revenue growth of 27%. 
&#8220;Sales remained strong throughout the quarter, including with respect to point of sale products compared to the prior year. We are continuing to execute at the elevated levels we saw as we exited fiscal year 2025 and are well positioned to achieve our 2026 fiscal year financial plan,&#8221; said Dave Wood, CFO of Agilysys.
AGYS Price Action: <a href="http://benzinga.com/quote/AGYS">Agilysys shares</a> were down 11.07% in after-hours, trading at $104 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46533157/steel-dynamics-stock-sinks-after-q2-results-miss-estimates-details">Steel Dynamics Stock Sinks After Q2 Results Miss Estimates: Details</a></li>
</ul>
Photo: Shutterstock.

Guidance

Movers

AGYS

Agilysys Stock Tumbles On Q1 Earnings

Offerings

Equitable Holdings Files For Mixed Shelf Offering; Size Not Disclosed

Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) stock traded higher on Monday after Morgan Stanley weighed in on the stock. Here&#8217;s what you need to know.
What To Know: Morgan Stanley maintained an Overweight rating on Alphabet and raised its price target from $185 to $205.
The company is set to report second quarter earnings on Wednesday after the market closes.
Analysts estimate earnings per share of $2.17 and revenue of $93.72 billion. Over the past few quarters, the company has beaten both EPS and revenue expectations.
In the first quarter, Alphabet reported earnings of $2.81 per share, topping the consensus estimate of $2.02. Revenue came in at $90.23 billion, beating the $89.20 billion estimate by 1.16% and marking a 12% year-over-year increase.
The company broke down its first-quarter results further, noting a 10% year-over-year increase in Google Services revenue to $77.3 billion, driven by strong performance across Google Search, subscriptions, platforms, and devices. Google Cloud revenue rose 28% to $12.3 billion, led by growth in Google Cloud Platform.
Analyst Changes: Ahead of the earnings report, multiple other analysts have issued price target adjustments.
<ul class="wp-block-list">
<li>UBS analyst Lloyd Walmsley maintained a Neutral rating on Alphabet and raised the price target from&nbsp;$186&nbsp;to&nbsp;$192.</li>
<li>BMO Capital analyst Brian Pitz reiterated an Outperform rating on Alphabet and raised the price target from&nbsp;$200&nbsp;to&nbsp;$208.</li>
</ul>
The consensus price target for Alphabet is $163.07, with the lowest price target at $115 and the highest price target at $235.
How To Buy Alphabet Stock
By now you're likely curious about how to participate in the market for Alphabet &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
See Also: <a href="https://www.benzinga.com/trading-ideas/previews/25/07/46525850/general-motors-q2-preview-ev-strength-could-seal-13th-straight-revenue-beat">General Motors Q2 Preview: EV Strength Could Seal 13th Straight Revenue Beat</a>
GOOG Price Action: At the time of writing, Alphabet stock closed Monday up 2.8% at $191.15, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Image via Shutterstock

GOOG

GOOGL

Alphabet Stock Is Trading Higher Monday: What's Going On?

<a href="https://www.semafor.com/article/07/21/2025/berkshire-bnsf-bankers-railroad-merger">https://www.semafor.com/article/07/21/2025/berkshire-bnsf-bankers-railroad-merger</a>

BRK/A

BRK/B

'Berkshire-owned BNSF taps bankers for its own rail acquisition'- Semafor

RBB Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBB#NASDAQ">RBB</a>) reported quarterly earnings of $0.36 per share which met the analyst consensus estimate. This is a 7.69 percent decrease over earnings of $0.39 per share from the same period last year. The company reported quarterly sales of $35.812 million which beat the analyst consensus estimate of $29.601 million by 20.98 percent. This is a 30.45 percent increase over sales of $27.453 million the same period last year.

Earnings Beats

UPDATE: RBB Bancorp Q2 Adj. EPS $0.36, Inline, Sales $35.812M Beat $29.601M Estimate

Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) has outperformed the market over the past 10 years by 7.59% on an annualized basis producing an average annual return of 19.22%. Currently, Autodesk has a market capitalization of $63.15 billion. 
Buying $100 In ADSK: If an investor had bought $100 of ADSK stock 10 years ago, it would be worth $578.18 today based on a price of $295.16 for ADSK at the time of writing.
<h3>Autodesk's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753132512_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADSK

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

MSFT

Reuters Cites Google Saying At Least Some Of Microsoft Server Hacks Carried Out By 'China-Nexus Threat Actor

<a href="https://www.wsj.com/tech/ai/softbank-openai-a3dc57b4">https://www.wsj.com/tech/ai/softbank-openai-a3dc57b4</a>

'SoftBank and Open AI's $500 Billion AI Project Struggles to Get Off Ground'- WSJ

Set forth below are preliminary estimates of selected unaudited financial information and other information for the three months ended June 30, 2025, and actual unaudited financial results for the three months ended June 30, 2024. We have provided ranges of certain preliminary results below because our closing procedures for our fiscal quarter ended June 30, 2025 are not yet complete. These ranges are based on the information available to us as of the date of this press release. Our final results remain subject to customary closing procedures or subsequent events, however we do not expect our final results to materially differ from the preliminary results shown below. These preliminary estimates are forward-looking statements. Our unaudited financial results as of the three months ended June 30, 2025 are not yet finalized. During the course of the preparation of our unaudited financial statements and the notes thereto by management, additional items that require adjustments to the preliminary results presented below may be identified.
The preliminary results provided below do not represent a comprehensive statement of our financial results and should not be viewed as a substitute for the financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP). In addition, the preliminary results for the three months ended June 30, 2025 are not necessarily indicative of the results to be achieved in any future period.
&nbsp;
The estimates of Karman&#39;s revenue, gross profit, pretax income, net income, funded backlog and adjusted EBITDA, as of June 30, 2025 are preliminary, have not been audited, do not present all information necessary for an understanding of Karman&#39;s financial condition as of June 30, 2025, and are subject to change upon completion of Karman&#39;s financial statement closing procedures. The preliminary financial data included in the above has been prepared by, and is the responsibility of, Karman&#39;s management. Karman&#39;s independent registered public accounting firm has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, Karman&#39;s independent registered public accounting firm does not express an opinion or any other form of assurance with respect thereto.
For the three months ended June 30, 2025, we expect revenue to be between $114.50 million and $115.00 million, representing an estimated increase of approximately 34.6% and 35.2%, compared to revenue of $85.04 million for the three months ended June 30, 2024.
For the three months ended June 30, 2025, we expect total gross profit to be between $46.70 million and $47.00 million, compared to total gross profit of $34.59 million for the three months ended June 30, 2024
For the three months ended June 30, 2025, we expect income before provision for income taxes to be between $8.31 million and $8.40 million, compared to income before provision for income taxes of $4.92 million for the three months ended June 30, 2024.
For the three months ended June 30, 2025, we expect net income to be between $6.17 million and $6.20 million, compared to net income of $4.60 million for the three months ended June 30, 2024.
For the three months ended June 30, 2025, net income margin is expected to be 5.4%, compared to net income margin of 5.4% for the three months ended June 30, 2024.
For the three months ended June 30, 2025, we expect funded backlog to be between $712.00 million and $715.00 million, representing an estimated increase of approximately 34.8% and 35.4%, compared to funded backlog of $528.01 million for the three months ended June 30, 2024.
For the three months ended June 30, 2025, Adjusted EBITDA is expected to be between $34.85 million and $35.15 million, compared to Adjusted EBITDA of $27.42 million for the three months ended June 30, 2024. For the three months ended June 30, 2025, Adjusted EBITDA margin is expected to be between 30.4% and 30.6%, compared to Adjusted EBITDA margin of 32.2% for the three months ended June 30, 2024.

KRMN

Karman Space & Defense Releases Preliminary Q2 Fiscal Year 2025 Financial Results; Q2 Revenue Expected Between $114.50M-$115.00M, Up 34.6%-35.2% YoY

AutoCanada Inc. (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ACQ#TSX">ACQ</a>), a multi-location North American automobile dealership group, today announced that it has selected CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>), the fastest-growing automotive shopping site in Canada1, as its preferred partner in Canada. Through this long-term relationship, AutoCanada will have access to the power and reach of CarGurus&#39; leading listings marketplace, advanced digital marketing and retail solutions, and market intelligence powered by proprietary data and predictive insights.
AutoCanada dealers will benefit from CarGurus&#39; solutions that help maximize visibility, connect with ready-to-buy shoppers, and make more data-informed decisions on vehicle pricing, inventory management, and digital advertising. The group&#39;s 64 franchised dealerships and three used car dealerships in Canada will also have ongoing access to strategic consultation from CarGurus&#39; in-person dealer engagement team, helping them navigate shifting market dynamics and consumer behavior.

Global

CARG

CarGurus Named Preferred Partner By AutoCanada To Enhance Digital Strategy Across Dealerships

<h3>Gainers</h3>
<ul>
<li>Genius Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) shares moved upwards by 7.5% to $1.29 during Monday's after-market session. The market value of their outstanding shares is at $118.9 million. </li>
<li>Children's Place (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLCE#NASDAQ">PLCE</a>) shares moved upwards by 4.98% to $5.48. The company's market cap stands at $114.1 million. </li>
<li>Kaival Brands Innovations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KAVL#NASDAQ">KAVL</a>) shares moved upwards by 4.16% to $0.5. The market value of their outstanding shares is at $5.8 million. </li>
<li>Brilliant Earth Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRLT#NASDAQ">BRLT</a>) shares rose 4.02% to $1.55. The market value of their outstanding shares is at $20.9 million. </li>
<li>SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) stock rose 3.98% to $26.25. The market value of their outstanding shares is at $2.7 billion. </li>
<li>TCTM Kids IT Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSA#NASDAQ">VSA</a>) shares rose 3.33% to $1.86. The company's market cap stands at $17.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lindblad Expeditions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIND#NASDAQ">LIND</a>) stock decreased by 8.0% to $11.36 during Monday's after-market session. The company's market cap stands at $681.1 million. </li>
<li>Tuniu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOUR#NASDAQ">TOUR</a>) stock fell 3.79% to $0.84. The company's market cap stands at $99.8 million. </li>
<li>Newton Golf (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTG#NASDAQ">NWTG</a>) stock fell 3.66% to $1.58. The market value of their outstanding shares is at $6.7 million. </li>
<li>Golden Heaven Group Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) shares fell 3.4% to $0.68. The company's market cap stands at $34.6 million. </li>
<li>Perfect Moment (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PMNT#AMEX">PMNT</a>) stock fell 3.34% to $0.35. </li>
<li>Autozi Internet Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZI#NASDAQ">AZI</a>) shares decreased by 3.32% to $0.26. The company's market cap stands at $29.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BRLT

GDHG

KAVL

LIND

NWTG

PLCE

PMNT

SBET

TOUR

12 Consumer Discretionary Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) shares moved upwards by 48.9% to $460.02 during Monday's after-market session. The market value of their outstanding shares is at $8.9 billion. The company's, Q2 earnings came out today. </li>
<li>Genelux (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLX#NASDAQ">GNLX</a>) stock increased by 7.65% to $3.78. The company's market cap stands at $125.7 million. </li>
<li>Rafael Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFL#NYSE">RFL</a>) stock rose 7.54% to $2.28. The market value of their outstanding shares is at $72.3 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock moved upwards by 7.37% to $12.52. The market value of their outstanding shares is at $20.7 million. </li>
<li>Ovid Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OVID#NASDAQ">OVID</a>) stock rose 7.36% to $0.65. The company's market cap stands at $39.1 million. </li>
<li>Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) shares increased by 6.81% to $160.0. The company's market cap stands at $7.8 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares declined by 9.8% to $0.02 during Monday's after-market session. The market value of their outstanding shares is at $7.8 million. </li>
<li>Barinthus Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) shares fell 9.65% to $1.78. The market value of their outstanding shares is at $60.4 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) stock decreased by 9.51% to $0.12. The company's market cap stands at $1.2 million. </li>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) shares declined by 7.07% to $0.27. The market value of their outstanding shares is at $11.7 million. </li>
<li>Neuraxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NRXS#AMEX">NRXS</a>) stock fell 6.6% to $2.55. The company's market cap stands at $24.9 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock fell 6.11% to $0.54. The market value of their outstanding shares is at $25.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BRNS

CYCC

DHAI

GNLX

HCTI

MEDP

NRXS

ONMD

OVID

TNFA

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Professional Diversity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) shares moved upwards by 13.9% to $2.9 during Monday's after-market session. The company's market cap stands at $6.0 million. </li>
<li>Dragonfly Energy Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) shares moved upwards by 9.94% to $0.29. The company's market cap stands at $1.5 million. </li>
<li>NeoVolta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOV#NASDAQ">NEOV</a>) shares rose 9.61% to $4.9. The company's market cap stands at $155.6 million. </li>
<li>Grab Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) shares rose 9.34% to $5.85. The company's market cap stands at $21.5 billion. </li>
<li>Linkers Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNKS#NASDAQ">LNKS</a>) stock rose 7.05% to $0.59. The market value of their outstanding shares is at $7.4 million. </li>
<li>Euro Tech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLWT#NASDAQ">CLWT</a>) shares rose 6.95% to $1.23. The market value of their outstanding shares is at $9.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lichen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) stock declined by 5.5% to $4.16 during Monday's after-market session. The market value of their outstanding shares is at $2.7 million. </li>
<li>Roma Green Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROMA#NASDAQ">ROMA</a>) shares declined by 5.24% to $3.35. The company's market cap stands at $52.1 million. </li>
<li>ATIF Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAI#NASDAQ">ZBAI</a>) stock decreased by 5.14% to $0.47. The market value of their outstanding shares is at $9.1 million. </li>
<li>Safe Pro Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPAI#NASDAQ">SPAI</a>) shares decreased by 5.09% to $3.55. The company's market cap stands at $60.6 million. </li>
<li>WF Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WFF#NASDAQ">WFF</a>) stock decreased by 4.24% to $1.13. The market value of their outstanding shares is at $28.7 million. </li>
<li>Spire Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) shares fell 4.23% to $11.55. The market value of their outstanding shares is at $380.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLWT

DFLI

GRAB

IPDN

LICN

LNKS

NEOV

ROMA

SPAI

SPIR

ZBAI

12 Industrials Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Auddia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUUD#NASDAQ">AUUD</a>) stock moved upwards by 6.5% to $4.39 during Monday's after-market session. The market value of their outstanding shares is at $2.6 million. </li>
<li>CVD Equipment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVV#NASDAQ">CVV</a>) shares moved upwards by 6.32% to $3.7. The company's market cap stands at $25.3 million. </li>
<li>Mobilicom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOB#NASDAQ">MOB</a>) shares rose 4.81% to $3.7. The company's market cap stands at $30.4 million. </li>
<li>Indie Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) shares moved upwards by 4.76% to $4.62. The company's market cap stands at $912.0 million. </li>
<li>MMTEC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) shares increased by 4.52% to $0.92. The company's market cap stands at $22.1 million. </li>
<li>SEALSQ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) shares rose 3.79% to $3.56. The market value of their outstanding shares is at $435.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ReAlpha Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>) shares declined by 50.9% to $0.42 during Monday's after-market session. The market value of their outstanding shares is at $10.6 million. </li>
<li>Agilysys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>) shares declined by 10.22% to $105.0. The market value of their outstanding shares is at $3.2 billion. The company's, Q1 earnings came out today. </li>
<li>Mobix Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBX#NASDAQ">MOBX</a>) shares declined by 5.94% to $1.11. The market value of their outstanding shares is at $46.0 million. </li>
<li>Robot Consulting Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAWR#NASDAQ">LAWR</a>) shares decreased by 3.89% to $3.21. The market value of their outstanding shares is at $170.9 million. </li>
<li>Cambium Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) shares declined by 3.68% to $1.31. The market value of their outstanding shares is at $27.0 million. </li>
<li>KVH Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KVHI#NASDAQ">KVHI</a>) shares declined by 3.58% to $5.12. The market value of their outstanding shares is at $104.8 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRE

AUUD

CMBM

INDI

KVHI

LAES

LAWR

MOBX

12 Information Technology Stocks Moving In Monday's After-Market Session

Press Releases

Nkarta to Participate in Upcoming Investor Conference

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

Nkarta to Participate in an Upcoming Investor Conference

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

Nkarta to Participate in March Investor Conferences

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Nkarta to Participate in an April Investor Conference

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

Comments

Nkarta

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO